Actively Recruiting
Effects of Cognitive Remediation Therapy on EEG and Emotional Regulation in Schizophrenia: A Randomized Controlled Study
Led by Beykoz University · Updated on 2025-04-20
60
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
B
Beykoz University
Lead Sponsor
U
Uskudar University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating whether Cognitive Remediation Therapy (CRT) can improve attention, memory, and emotional regulation in people diagnosed with schizophrenia. This randomized controlled trial includes 60 participants: 30 with schizophrenia and 30 healthy individuals matched by age and gender. The study focuses on understanding if a 12-week CRT program affects brain activity and emotional regulation, using EEG and galvanic skin response (GSR) measurements as key indicators. Participants with schizophrenia will be randomly assigned to either receive 12 weekly CRT sessions, each lasting about 60 minutes and targeting cognitive skills like working memory and executive function, or be placed on a waitlist without therapy during this period. Healthy participants will undergo baseline brain and emotional assessments but will not receive CRT. The study involves EEG recordings of brain responses and GSR to emotional stimuli, along with behavioral and cognitive tests. Throughout the study, all participants will complete memory, emotion recognition tasks, and self-report questionnaires on cognition and emotional well-being. Researchers will compare results before and after the intervention to measure changes in brain-based markers, cognitive function, and quality of life. Safety and adherence will be monitored, and the study's duration for participants is 12 weeks with assessments at baseline and post-intervention.
CONDITIONS
Brief Title
Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with schizophrenia according to DSM-5 criteria (schizophrenia group)
- Age between 18 and 55 years
- Clinically stable with no hospitalization or medication changes within 1 month
- Minimum primary school education
- Able to provide informed consent
- Right-handed (for EEG protocol consistency)
- No history of psychiatric or neurological disorders (healthy control group)
- Age- and gender-matched to schizophrenia group (healthy controls)
- No current medication affecting the central nervous system (healthy controls)
- Able to provide informed consent (healthy controls)
- Right-handed (healthy controls)
You will not qualify if you...
- Current or past substance use disorder within the past year
- Comorbid neurological illness such as epilepsy or traumatic brain injury
- Current use of benzodiazepines or medications significantly affecting cognitive function
- Intellectual disability or Montreal Cognitive Assessment (MoCA) score less than 20
- Visual or hearing impairments that could interfere with task performance
- Participation in psychological interventions in the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - 12 weeks
Participants diagnosed with schizophrenia receive Cognitive Remediation Therapy consisting of weekly 60-minute sessions targeting attention, memory, executive function, and emotion regulation.
Weekly visits for 12 sessions (in-person)
Duration - Up to 2 weeks before and after treatment
Participants are assessed before and after the treatment period to measure changes in EEG, skin conductance, cognitive function, and emotional regulation.
2 visits (in-person) for baseline and post-treatment assessments
Trial Site Locations
Total: 1 location
1
Beykoz University
Istanbul, Turkey (Türkiye), 34820
Actively Recruiting
Research Team
E
Eda Yılmazer, Phd
M
Metin Çınaroğlu, Phd
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here